Pierre Tiberghien

Title: Pierre Tiberghien: Innovator in Biotechnology

Introduction

Pierre Tiberghien is a notable inventor based in Paris, France. He has made significant contributions to the field of biotechnology, particularly in the development of diagnostic tools and therapeutic methods. With a total of 2 patents, Tiberghien's work is recognized for its potential impact on medical science.

Latest Patents

Tiberghien's latest patents include innovative technologies such as the Truncated CD20 protein, deltaCD20. This patent features a diagnostic kit comprising an oligonucleotide probe for the mRNA encoding a polypeptide that has an amino acid sequence substantially identical to that of SEQ ID NO: 2. Another significant patent involves an isolated nucleic acid sequence encoding the CD20 gene, which includes SEQ ID NO: 5. This patent also describes a recombinant vector that comprises a nucleic acid sequence placed under the control of elements required for expression in a host cell, along with a method for improving treatment efficacy using the nucleic acid sequence.

Career Highlights

Pierre Tiberghien is currently associated with the establishment known as Etablissement Francais Du Sang. His work there focuses on advancing research in blood-related medical technologies. His contributions have been instrumental in enhancing diagnostic and therapeutic approaches in the field.

Collaborations

Tiberghien has collaborated with notable colleagues such as Christophe Ferrand and Marina Deschamps. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

In summary, Pierre Tiberghien is a distinguished inventor whose work in biotechnology has led to significant advancements in medical diagnostics and treatment methods. His patents reflect a commitment to improving healthcare through innovative solutions.